Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

Although research and development funding for tuberculosis reached new heights last year, the total fell substantially short ...

HHMI will bar institutions that already have two or more beneficiaries of its Investigator Program from applying for funds to ...

SAN DIEGO — Brian Koffman found himself in a situation a couple years ago that most chronic lymphocytic leukemia patients ...

Kaadan is an assistant professor and vascular medicine attending in the cardiology division at Rush University Medical Center ...

Testing of samples taken from a child in California thought to have contracted H5N1 bird flu after drinking raw milk turned ...

STAT reporters discuss why drugmakers have not lobbied against RFK Jr.'s nomination to lead HHS and the struggles around ...

Some of the remarks could be mistaken for political ads that might run if Republicans pursue Medicaid cuts or don’t extend ...

Investors in Padlock Therapeutics have accused Bristol Myers Squibb of reneging on payments of up to $450 million negotiated ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.